anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All eligible patients will begin asciminib in combination with a TKI on cycle 1 day 1 of the combination phase. They will continue combination therapy for a total of 12 cycles (minimum of 12 months). Each cycle will be \~28 days. At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, patients will also discontinue their TKI and be monitored off treatment. The primary endpoint of this study is the 12-month 'second' TFR rate after completion of 12 cycles of combination therapy. Patients will remain in the TFR phase of the study for up to three years and will have central PCR testing during the first two years. Therefore, the total duration of the subject participation trial will be approximately five years (one year on combination treatment phase plus three years in the TFR phase plus one year of long-term follow-up post TFR or early discontinuation.
Patients should be informed that Amoxicillin and Clavulanate Potassium may be taken every 8 hours or every 12 hours, depending on the dose prescribed. Each dose should be taken with a meal or snack to reduce the possibility of gastrointestinal upset.

Patients should be counseled that antibacterial drugs, including Amoxicillin and Clavulante Potassium, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Amoxicillin and Clavulante Potassium is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Amoxicillin and Clavulante Potassium or other antibacterial drugs in the future.

Counsel patients that diarrhea is a common problem caused by antibacterials, and it usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibacterial. If diarrhea is severe or lasts more than 2 or 3 days, patients should contact their physician. 

Patients should be advised to keep suspension refrigerated. Shake well before using. When dosing a child with the suspension (liquid) of Amoxicillin and Clavulante Potassium, use a dosing spoon or medicine dropper. Be sure to rinse the spoon or dropper after each use. Bottles of suspension of Amoxicillin and Clavulante Potassium may contain more liquid than required. Follow your doctor’s instructions about the amount to use and the days of treatment your child requires. Discard any unused medicine.

Patients should be aware that Amoxicillin and Clavulante Potassium contains a penicillin class drug product that can cause allergic reactions in some individuals.
Over recent years, researchers and practitioners have encountered massive and continuous improvements in the computational resources available for their use. This allowed the use of resource-hungry Machine learning (ML) algorithms to become feasible and practical. Moreover, several advanced techniques are being used to boost the performance of such algorithms even further, which include various transfer learning techniques, data augmentation, and feature concatenation. Normally, the use of these advanced techniques highly depends on the size and nature of the dataset being used. In the case of fine-grained medical image sets, which have subcategories within the main categories in the image set, there is a need to find the combination of the techniques that work the best on these types of images. In this work, we utilize these advanced techniques to find the best combinations to build a state-of-the-art lumber disc herniation computer-aided diagnosis system. We have evaluated the system extensively and the results show that the diagnosis system achieves an accuracy of 98% when it is compared with human diagnosis.
The REACT treatment concept aims at minimizing the metal burden, combining Passeo-18 Lux Drug-Coated Balloon (DCB) with Pulsar-18 thin struts bare metal stent, as low as reasonably achievable (ALARA), while benefiting from the antirestenotic properties of Paclitaxel. However, in order to optimally apply this selective stenting approach, it is needed to clearly identify when a stent is indicated. Angiographic images, even with additional projections, are sometimes insufficient to clearly determine if a dissection is flow-limiting and the subsequent stent requirement. There is currently no definition nor validated method to define flow-limiting dissection in the peripheral arteries. Even though it has been widely used, the classification developed by the National Heart, Lung, and Blood Institute to grade coronary artery dissection as A to F19, based on angiographic appearance cannot be extrapolated to peripheral arteries.

Therefore, the purpose of the study is to evaluate the incremental value of several adjunctive procedural assessments to standard angiography to identify flow-limiting dissection and residual stenosis, and better inform the operator on the stent requirement. In addition, the study will evaluate the safety and efficacy of the REACT algorithm.
ABSTRACT OF THE DISCLOSURE         Known neuroleptic drugs used to treat schizophrenia include phenothiazines such as chloropromaxine; butyrophenones such as haloperiodal and others such as pimocide and clozapine.  Underirable side effects of neuroleptic drugs include sedation and tardive dyskinesias.  The latter side effect is particularly important because it results in involuntary muscle movements especially of the face and mouth which become reversible. The onset of this side effect is directly related to the amounts of and length of time which a neuroleptic drug is used in treatment.  There has now been discovered a composition for treating schizophrenia and a method and composition for potentiating the beneficial effects and for reducing the side effects of neuroleptic drugs.  The foregoing results are obtained by administering to a schizophrenic an effects amount of a gabergic compound or by coadministering to a schizophrenic a neuroleptic drug and a potentiating amount of a gabergic compound such as gammahydroxybutyrolac-tone, gammahydroxybutyrate, aminooxyacetic acid or a compound having the structural formula   wherein R is halogen or trifluoromethyl and salts thereof.  The present invention further relates to a composition comprising a neuroleptic drug and a potentiating amount of a gabergic compound together with a suitable pharmaceutical carrier.
In addition to the built-in PI education in the NIS that nurses use every day, it also provides a flipped digital learning plan course unit, which can be self-study courses anytime, anywhere, without being restricted by time and space. And hold a 4-hour physical course for participants.
The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy. By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
PURPOSE:To obtain the subject dental composite resin capable of providing a cured material excellent in abrasion resistance by using a bisurethane acrylate methacrylate as a polymerizable monomer in combination with a polymerization initiator and a filler. CONSTITUTION:The objective composite resin is obtained by using a bisurethane acrylate methacrylate (e.g. a compound of formula II) of the formula [R<1> and R<2> are each an acryloyloxyalkyl; R<3> is H or an acryloyloxyalkyl; R<4> is a (substituted)aliphatic alkylene; R<5> and R<6> are each a methacryloyloxyalkyl; R<7> is H or a methacryloyloxyalkyl; n is 0 or 1] as a polymerizable monomer in combination with a polymerization initiator (e.g. camphorquinone) and a filler (e.g. superfine silica powder and ground silica powder). The above- mentioned polymerizable monomer is obtained, e.g. by reacting an organic diisocyanate containing two isocyanate groups in the molecule with a methacrylic acid ester containing an OH group in the molecule and an acrylic acid ester also containing an OH group in the molecule.
After assignment to SHE, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session SHE programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of SHE. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
Abdominal pain is present in 81% of children and adolescents with CP and ARP. Effective treatments that target pain in these children will lessen the risk of opioid exposure and continued pain and disability into adulthood. We plan to recruit a large multicenter sample of 260 children and adolescents (ages 10-19 years) with CP/ARP and their parents from INSPPIRE 2 (INSPPIRE:INternational Study Group of Pediatric Pancreatitis: In search for a cuRE) centers and pancreatitis community groups (e.g. NPF) to evaluate the efficacy of WebMAP, a web-based cognitive behavioral pain management program (CBT). The study design is a two (group) x three (time point) randomized, controlled, double-blinded trial. Participants will be randomly assigned to receive online access to either pain education (WebED) or CBT (WebMAP) over an 8-10 week treatment period. The primary study outcome is abdominal pain symptoms measured at pre-treatment, immediately post-treatment, and at 6-month follow-up. Secondary outcomes include pain-related disability, health-related quality of life, depression and anxiety symptoms, and medication use. This project represents a significant advance in pain management for children with CP/ARP by evaluating the first ever nonpharmacologic pain intervention in these patients, which may guide future developments in the management of chronic pain associated with CP/ARP.
OBJECTIVE: Optimization of the method of puncture treatment of acute bacterial maxillary sinusitis (ABMS) through the development of original devices for drainage of the maxillary sinus (MS).
MATERIAL AND METHODS: Registration and comparative analysis of the results of puncture methods of treatment of 120 patients with ABMS using developed new original devices for drainage of MS with one channels and with two channels in comparison with the Kulikovsky's needle (KN) was carried out. Based on the results of the analysis, the effectiveness of the original devices was assessed. During the clinical study, patients were divided into two groups: in group I, patients underwent of the MS puncture using KN, in group II, using original devices. Groups I and II, depending on the absence or presence of a block of the natural anastomosis MS, was divided into subgroups A and B, respectively. After puncture of the MS, the pain syndrome was assessed by patients using Visual Analogue Scale (VAS) and by doctors - using Touch Visual Pain (TVP) scale.
RESULTS: Our study showed that when puncturing the upper jaw with an original needle with one channels and with two channels, compared with the use of KN, there is a decrease in pain (the average VAS score was 1.5±0.3 and 1.7±0.3 points, respectively; the average TVP scale score was 0.9±0.2 and 1.8±0.3 points, respectively, the difference is significant, p≤0.05). Patients of subgroup IB were manipulated with two KN, patients of subgroup IIB manipulated using the original device with two channels without an additional needle (the average VAS score was 3.0±0.4 and 1.3±0.3 points, respectively; the average TVP scale score was 2.7±0.4 and 1.0±0.2 points, respectively, the difference is significant, p≤0.05). The doctors also assessed the devices used for puncture of the upper jaw. As a result of the study, the high efficiency and safety of using new original devices was established.
The short periods of incubation during egg storage (SPIDES) method enhances the quality of chicks and improves hatching rates. Additionally, embryonic thermal conditioning (TC) is a technique used to enhance thermotolerance in birds. Previous studies have evaluated the effects of SPIDES and embryonic TC separately. Yet, our hypothesis postulated that a synergistic effect could be achieved by integrating TC and SPIDES, thereby enhancing the broilers' resilience to thermal stress. We conducted an experiment involving 800 Ross broiler eggs, divided into two groups. The first group, referred to as S0, was maintained under standard storage room conditions and acted as our control group. The second group, known as S1, underwent a process called SPIDES for 5 h at a temperature of 37.8 ± 0.1 °C, on three occasions: days 5, 10, and 15 following egg collection. Upon reaching the 14th day of incubation (DOI), each of these primary groups was randomly subdivided into two equal subgroups. The control subgroup, designated as TC0, remained in the usual incubation conditions. Meanwhile, the other subgroup, TC1, was subjected to prenatal heat conditioning at a temperature of 39.5 ± 0.1 °C for 6 h per day, commencing on the 14th embryonic day (E) and extending until the 18th embryonic day (E). This experimental setup resulted in four distinct experimental subgroups: S0TC0, S1TC0, S0TC1, and S1TC1. The findings indicated that the combined application of SPIDES and TC had a significant positive effect on chick performance after hatching. Specifically, the (S1TC1) group exhibited the heaviest live body weight (LBW) and body weight gain (BWG) at the marketing age in comparison to the other groups. Furthermore, both SPIDES and TC had a positive influence on the relative weights of breast muscles and their histological measurements. The (S1TC1) group displayed significantly higher values in terms of the relative weight of breast muscles and the number of myocytes. In conclusion, SPIDES and TC have beneficial effects on pre- and post-hatch characteristics of broiler chicks up until the marketing age. Additionally, TC techniques improve chick performance, particularly under conditions of heat stress, and enhance the yield of breast muscle in later stages of life.
Improved outcomes for epilepsy treatment depend on a continuous supply and daily adherence to anti-seizure medications (ASMs). In Kilifi County, the treatment gap which includes both the diagnostic and adherence gap, is greater than 70% and investigators have found interruption of supply of ASMs to peripheral clinics, distance from clinic and lack of availability of ASMs, to be barriers to adherence. In Nairobi County, factors such as environment hazards, lack of social amenities and correlates of poverty are preponderant in slums, but the prevalence of epilepsy has not been studied in such settings and consequently, the adherence gap remains unknown. Innovative mobile Health (mHealth) strategies including messages delivered by mobile phones have been used to ensure an adequate supply of drugs in health centres, and daily mobile messages have improved adherence to medication in Human Immunodeficiency Virus (HIV) programs, for example. Text messaging requires that the patient has access to a mobile phone and can understand the text message. Multimedia messaging, such as simple pictures, may improve understanding of the necessity to take medication, particularly in people who are illiterate, and we will explore this as an avenue to improve uptake.

The investigators plan to randomize 1200 people with epilepsy at each site, from a defined area in Kilifi and Nairobi County, Kenya. They will be divided into four groups of 300 each, to receive either text SMS, graphic SMS, both text and graphic or SMS on public health promotion not related to epilepsy e.g. use of bednets (for comparison). The investigators aim is to i) describe the perceptions and perspectives of people with epilepsy and their caregivers on the use of text and graphic SMS reminders to improve adherence to ASMs, ii) compare the effectiveness of text versus graphic messaging service in improving adherence in people with epilepsy and to engage the County Departments of Health through current ongoing training and capacity building studies to maintain supply of ASMs in peripheral clinics iii) identify the factors associated with improvement in adherence, improved QoL and reduction in stigma among people with epilepsy and family members and iv) conduct cost-effectiveness assessment for the roll out of the intervention. Besides medication-related messages, there will be other messages, from previous community-based feedback, selected to address stigmatization and improve quality of life. Blood-level monitoring and adherence questionnaires at baseline and during subsequent follow up visits will be used to assess as measures of medication adherence. If found useful, this intervention may be applicable for self-managing other chronic conditions in under-resourced settings.
Background: Breast cancer-related lymphedema (BCRL) is a disabling and frequently occurring condition after treatment for breast cancer. Studying lymph anatomy by means of indocyanine green (ICG) lymphography is a promising tool to help better understand BCRL. The aim of this study is to investigate the relation between ICG lymphography characteristics and the risk of developing BCRL. Methods and Results: Patients scheduled for breast surgery with either unilateral axillary lymph node dissection or sentinel lymph node biopsy between November 2017 and May 2019 were included. Patients were assessed at baseline and up to 36 months postsurgery. BCRL was defined as an increase of ≥5% relative arm volume difference compared with the presurgical difference. In total, 128 patients were included. During 36 months of follow-up, 45 patients (35.2%) developed BCRL. The number of lymph vessels before surgery was not a statistically significant risk factor for developing BCRL (p = 0.8485). However, an increase in the number of lymph vessels compared with baseline was a significant protective factor for developing BCRL (odds ratio = 0.8). An increase of one lymph vessel corresponds to a 19% relative risk reduction of developing BCRL. The presence of lymph nodes at baseline and the change in the presence of lymph nodes compared with baseline were no predictors for the development of BCRL (p = 0.0986 and p = 0.8910, respectively). Conclusions: An increase in the number of lymph vessels visualized by ICG lymphography compared with baseline is a protective factor for developing BCRL. Therapies with the ability to increase the number of lymph vessels can thus possibly decrease the risk of developing BCRL.
The recent evidence regarding the effectiveness of renal denervation (RDN) in blood pressure control is becoming increasingly substantial. However, many studies have excluded populations with severely impaired kidney function, even though these individuals have a higher prevalence of hypertension compared to the general population, and controlling their blood pressure is more challenging. The effectiveness and safety of RDN in patients with severe chronic kidney disease (CKD) lack strong evidence support. Concerns about worsening kidney function still exist, particularly in patients with CKD stage 5. We conducted an observational study involving 10 patients who were using at least 3 different antihypertensive medications and had an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2 but had not undergone dialysis. For these patients, we performed RDN via the radial artery approach, with the assistance of carbon dioxide (CO2) angiography. Utilizing this approach, the systolic 24-hour ambulatory blood pressure monitoring did not exhibit a significant decrease at 3 months; however, a significant reduction was observed at 6 months after RDN. We also minimized contrast agent usage, observed no kidney function decline 3 months post-RDN, and experienced no vascular-related complications. Using the radial artery approach and CO2 angiography assistance for RDN may be an effective and safe blood pressure control method for patients with severe kidney impairment.
Ruxolitinib will be administered over a 28-day cycle, which will be repeated 6 more times in the absence of intolerable toxicity, disease progression, patient withdrawal of consent, or investigator decision to end therapy. The dose and schedule have been adapted from the product monograph for myelofibrosis. The starting dose will be 20 mg orally twice a day with normal .platelet and absolute neutrophil counts and no hepatic and renal impairment.
A skin external composition for moisturizing, which contains an Astragalus membranaceus Bunge. extract is provided to increase skin moisturizing and improve xeroderma, atopic dermatitis, contact dermatitis or psoriasis. A skin external composition comprises 0.0001-20% by weight of Astragalus membranaceus Bunge. extract as an effective ingredient. The Astragalus membranaceus Bunge. extract is isolated in a extractor having a pottery. The extractor comprises a main body (110), cover of main body, heating part (130), pottery (140), and gas valve (150). A method for manufacturing the Astragalus membranaceus Bunge. extract comprises: a step of putting the material to be extracted and extraction solvent in a regular ratio; a step of closing the cover to seal the main body; a step of injecting gas into the body and discharging the air from the body; a step of supplying hot water to heat the body; a step of discharging the hot water from the body to cool the body; a step of discharging the gar from the body; and a step of opening the cover of body and collect the extract.
The liver is a complex organ that performs vital functions in the body. Despite its extraordinary regenerative capacity compared to other organs, exposure to chemical, infectious, metabolic and immunologic insults and toxins renders the liver vulnerable to inflammation, degeneration and fibrosis. Abnormal wound healing response mediated by aberrant signaling pathways causes chronic activation of hepatic stellate cells (HSCs) and excessive accumulation of extracellular matrix (ECM), leading to hepatic fibrosis and cirrhosis. Fibrosis plays a key role in liver carcinogenesis. Once thought to be irreversible, recent clinical studies show that hepatic fibrosis can be reversed, even in the advanced stage. Experimental evidence shows that removal of the insult or injury can inactivate HSCs and reduce the inflammatory response, eventually leading to activation of fibrolysis and degradation of ECM. Thus, it is critical to understand the role of gene-environment interactions in the context of liver fibrosis progression and regression in order to identify specific therapeutic targets for optimized treatment to induce fibrosis regression, prevent HCC development and, ultimately, improve the clinical outcome.
* Aseptic technique must be maintained at all times. 
  * Do not use unless solution is clear/colorless and seal is intact. Product that exhibits a slight yellow color should not be used. Product instability has been observed after continuous exposure at high temperature (after 6 months at 40 °C and after 9 months at >30 °C). 
  * This product contains no bacteriostatic or antimicrobial agents and is intended for single use only. 
  * Rx Only - Federal (USA) law prohibits dispensing without prescription.